
News|Articles|February 13, 2019
Gamifant for Primary Hemophagocytic Lymphohistiocytosis
Author(s)Drew Boxler
Advertisement
Gamifant (emapalumab-lzsg, Sobi)
Indications: patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
Dosage: 1 mg/kg as an intravenous infusion over 1 hour twice per week; Administer dexamethasone concomitantly with GAMIFANT.
Contraindications:None
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Targeted Coordination Is Crucial in Boosting Pneumococcal Vaccine Coverage
2
CoronaVac Improves Outcomes of COVID-19 for Patients With Schizophrenia
3
From Policy to Practice: Elevating Pharmacy’s Role in Quality and Patient Safety
4
Reducing HIV Stigma Can Improve Patient Care, Provider Connectivity
5
















































































































